使用一种新的患者报告结局指标评估肉毒杆菌毒素A治疗眉间纹和外眦纹的患者满意度。

Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.

作者信息

Rivers Jason K, Bertucci Vince, McGillivray William, Muhn Channy, Rosen Nathan, Solish Nowell, Weichman Barry M, Wheeler Sarah, Daniels Selena R, Gallagher Conor J

机构信息

*Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada; †Division of Dermatology, University of Toronto, Toronto, Ontario, Canada; ‡Project Skin MD Ltd., Vancouver, British Columbia, Canada; §Division of Dermatology, McMaster University, Hamilton, Ontario, Canada; ‖Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; ¶Peloton Advantage, Parsippany, New Jersey; #Allergan, Inc., Irvine, California.

出版信息

Dermatol Surg. 2015 Aug;41(8):950-9. doi: 10.1097/DSS.0000000000000424.

DOI:10.1097/DSS.0000000000000424

PMID:26218728

Abstract

BACKGROUND

Patient satisfaction with treatment is an important outcome in facial aesthetic medicine.

OBJECTIVE

To evaluate subject satisfaction with onabotulinumtoxinA treatment of glabellar lines (GL) and crow's feet lines (CFL) using the validated Facial Line Satisfaction Questionnaire (FLSQ).

METHODS

In this randomized double-blind study, subjects with moderate/severe GL and CFL received onabotulinumtoxinA (20 U, GL; 24 U, CFL) or placebo. Over 120 days, the following were assessed: satisfaction, achievement of treatment expectations, satisfaction with duration of treatment (FLSQ), severity of GL and CFL (Facial Wrinkle Scale [FWS]), and aesthetic improvement (Global Aesthetic Improvement Scale).

RESULTS

Satisfaction in the per-protocol population was significantly greater at Day 60 in the onabotulinumtoxinA group (n = 60) compared with placebo (n = 57) for GL (81.7% vs 0%; p < .001). Most subjects treated with onabotulinumtoxinA remained satisfied up to 120 days. Achievement of treatment expectations (86.7%; Day 60), satisfaction (81.7%; Day 60), and satisfaction with the duration of treatment (61.6%; Day 90) were significantly better with onabotulinumtoxinA than placebo (p < .001) for GL and CFL combined. Efficacy (FWS) and aesthetic improvement were observed in most subjects at Days 30 and 60, respectively.

CONCLUSION

High satisfaction rates are achieved and sustained in subjects treated with onabotulinumtoxinA for GL and CFL combined.

摘要

背景

患者对治疗的满意度是面部美容医学的一项重要成果。

目的

使用经过验证的面部皱纹满意度问卷（FLSQ）评估受试者对肉毒杆菌毒素A治疗眉间纹（GL）和鱼尾纹（CFL）的满意度。

方法

在这项随机双盲研究中，患有中度/重度眉间纹和鱼尾纹的受试者接受肉毒杆菌毒素A（20 U，眉间纹；24 U，鱼尾纹）或安慰剂治疗。在120天内，评估以下指标：满意度、治疗期望达成情况、对治疗持续时间的满意度（FLSQ）、眉间纹和鱼尾纹的严重程度（面部皱纹量表[FWS]）以及美学改善情况（整体美学改善量表）。

结果

在意向性分析人群中，与安慰剂组（n = 57）相比，肉毒杆菌毒素A组（n = 60）在第60天时眉间纹的满意度显著更高（81.7% 对0%；p < 0.001）。大多数接受肉毒杆菌毒素A治疗的受试者在12天内一直保持满意。对于眉间纹和鱼尾纹合并情况，肉毒杆菌毒素A在治疗期望达成情况（86.7%；第60天）、满意度（第60天）以及对治疗持续时间的满意度（第90天）方面均显著优于安慰剂（p < 0.001）。在第30天和第60天，分别在大多数受试者中观察到了疗效（FWS）和美学改善。